Joseph Todisco, Chief Executive Officer and Director of CorMedix Inc., filed a Form 4 on November 16, 2026, disclosing the open-market purchase of 80,000 shares of CorMedix common stock on November 13, 2026.
Key Highlights
- Reporting person: Joseph Todisco, serving as Chief Executive Officer and Director of CorMedix Inc. (NASDAQ:CRMD)
- Transaction: Purchase (transaction code P) of 80,000 shares of common stock on November 13, 2026
- Weighted average price: $4.89 per share, executed across multiple trades ranging from $4.85 to $5.00, inclusive
- Resulting ownership: 854,749 shares of common stock held directly following the transaction
- No derivative securities were reported as acquired, disposed of, or beneficially owned in Table II
Todisco's November 2026 Open-Market Purchase of CorMedix Common Stock
According to the Form 4 filed with the U.S. Securities and Exchange Commission on November 16, 2026, Joseph Todisco, CEO and Director of CorMedix Inc. (NASDAQ:CRMD), acquired 80,000 shares of the company's common stock on November 13, 2026. The filing reports the transaction under code "P," indicating an open-market purchase. The price listed in the filing is a weighted average of $4.89 per share, reflecting multiple individual trades executed at prices ranging from $4.85 to $5.00, inclusive.
As noted in the filing's explanation of responses, Todisco "undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected." Following the reported transaction, the filing states that Todisco directly holds 854,749 shares of CorMedix common stock. No indirect ownership or derivative securities positions were reported in Table II of the filing.
The filing was signed by Joseph Todisco and dated November 16, 2026. CorMedix Inc. is listed on NASDAQ under the ticker symbol CRMD, and its address of record for the reporting person is 389 Interpace Pkwy, Suite 450, Parsippany, New Jersey 07054.
What Was Disclosed
Joseph Todisco, CEO and Director of CorMedix Inc., disclosed the purchase of 80,000 shares of common stock on November 13, 2026, at a weighted average price of $4.89 per share, bringing his direct beneficial ownership to 854,749 shares.




Please wait processing your request...